'The risk of overtreatment of gender dysphoria is real.' ![]() It shows claims have doubled since 2017ĭr Abbasi added: 'Much of this clinical practice is supported by guidance from medical societies and associations, but closer inspection of that guidance finds that the strength of clinical recommendations is not in line with the strength of the evidence. The above graph shows insurance claims for puberty blockers in the United States by year, which delay the onset of secondary sexual characteristics - such as facial hair and a deeper voice in boys.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |